Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Tuesday morning. The firm issued a hold rating on the medical research company’s stock.

Other equities analysts also recently issued reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Monday, January 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.03 on Tuesday. The company has a market capitalization of $56.32 million, a P/E ratio of -2.86 and a beta of 0.58. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The company’s 50 day moving average price is $0.94 and its two-hundred day moving average price is $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, November 7th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.14 million. During the same quarter in the previous year, the business posted ($0.21) earnings per share. On average, analysts expect that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

Large investors have recently modified their holdings of the business. Atomi Financial Group Inc. purchased a new stake in Cytosorbents during the third quarter valued at about $51,000. Sargent Investment Group LLC raised its position in Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the period. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.